Bluebird Bio: Funding, Investors & Team (Sep 2026)
Bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
Bluebird Bio has raised $75.0M across 2 funding rounds on record, the most recent an undisclosed round announced in Feb 2025.
Bluebird Bio Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Bluebird Bio Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Bluebird Bio raised $75.0M in a Post-IPO Equity announced in Sep 2021.
3.4 years later, an undisclosed round was announced in Feb 2025 with no disclosed amount.
Bluebird Bio Founders and Leadership Team
Contact details for the Bluebird Bio team: 1 of 2 have an email address on file.
Start 14-day free trial →Bluebird Bio Funding Compared to Other Biotechnology Startups
Funded Startups Like Bluebird Bio in Biotechnology and Somerville
Companies Similar to Bluebird Bio
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Bluebird Bio Funding FAQs
What does Bluebird Bio do?
Bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
How much funding has Bluebird Bio raised?
Bluebird Bio has raised $75.0M across 2 rounds on record.
When did Bluebird Bio last raise funding?
Bluebird Bio's most recent funding round on record was announced in Feb 2025. The amount was not disclosed.
Who founded Bluebird Bio?
FundedIQ lists Philippe Leboulch (Founder) at Bluebird Bio.
Who is the CEO of Bluebird Bio?
Nick Leschly is listed as CEO at Bluebird Bio.
Where is Bluebird Bio headquartered?
Bluebird Bio is based in Somerville, Massachusetts, United States.
How many employees does Bluebird Bio have?
Bluebird Bio is in the 251-500 employee band.
About FundedIQ's Bluebird Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bluebird Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.